JS

Jeremy Springhorn

Chief Executive Officer at Nido Biosciences

Boston, Massachusetts

Investor
CEO
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Pharmaceutical Industry
Technology Transfer
Molecular Biology
Biopharmaceuticals
Lifesciences
Drug Discovery
Biotechnology
Business Strategy
Protein Chemistry
Business Development
Corporate Strategy Formulation
Corporate Development
Clinical Development
Drug Development
Immunology
Pharmacology
Oncology
Life Sciences
Infectious Diseases
Commercialization

Education

Lists including Jeremy

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14748 people

AM
AT
AS
AR

All Seed Investors

19691 people

Work Experience

NB
Nido Biosciences

2021

  • Chief Executive Officer

    2021

NP
NMD Pharma A/S

2019

  • Independent Director

    2019

u
uniQure

2017

  • Board Member

    2017

MT
Mythic Therapeutics

2017 - 2024

  • Member Of The Board Of Advisors

    2017 - 2024

SP
Syros Pharmaceuticals

2017 - 2021

  • Chief Business Officer

    2017 - 2021

FP
Flagship Pioneering

2015 - 2017

  • Partner, Corporate Development

    2015 - 2017

AP
Alexion Pharmaceuticals

2009 - 2015

  • VP, Corporate Strategy and Business Development

    2009 - 2015

AP
Alexion Pharmaceuticals

2006 - 2008

  • Head of Global Business Development and Corporate Strategy

    2006 - 2008

AP
Alexion Pharmaceuticals, Inc.

1992 - 2006

  • R&D Management

    1992 - 2006